S&P 500   4,172.98 (-0.77%)
DOW   32,815.86 (-0.69%)
QQQ   346.91 (-0.88%)
AAPL   178.67 (+0.77%)
MSFT   328.38 (-0.85%)
META   261.56 (-0.37%)
GOOGL   122.88 (-0.64%)
AMZN   119.25 (-1.98%)
TSLA   196.50 (-2.32%)
NVDA   383.03 (-4.51%)
NIO   7.31 (-1.35%)
BABA   78.36 (-0.39%)
AMD   118.86 (-5.12%)
T   15.80 (+1.02%)
F   12.03 (-4.45%)
MU   68.44 (-4.53%)
CGC   0.80 (-5.39%)
GE   100.36 (-1.99%)
DIS   87.42 (-0.46%)
AMC   4.41 (-4.75%)
PFE   37.59 (+1.57%)
PYPL   61.35 (-1.13%)
NFLX   391.19 (-0.46%)
S&P 500   4,172.98 (-0.77%)
DOW   32,815.86 (-0.69%)
QQQ   346.91 (-0.88%)
AAPL   178.67 (+0.77%)
MSFT   328.38 (-0.85%)
META   261.56 (-0.37%)
GOOGL   122.88 (-0.64%)
AMZN   119.25 (-1.98%)
TSLA   196.50 (-2.32%)
NVDA   383.03 (-4.51%)
NIO   7.31 (-1.35%)
BABA   78.36 (-0.39%)
AMD   118.86 (-5.12%)
T   15.80 (+1.02%)
F   12.03 (-4.45%)
MU   68.44 (-4.53%)
CGC   0.80 (-5.39%)
GE   100.36 (-1.99%)
DIS   87.42 (-0.46%)
AMC   4.41 (-4.75%)
PFE   37.59 (+1.57%)
PYPL   61.35 (-1.13%)
NFLX   391.19 (-0.46%)
S&P 500   4,172.98 (-0.77%)
DOW   32,815.86 (-0.69%)
QQQ   346.91 (-0.88%)
AAPL   178.67 (+0.77%)
MSFT   328.38 (-0.85%)
META   261.56 (-0.37%)
GOOGL   122.88 (-0.64%)
AMZN   119.25 (-1.98%)
TSLA   196.50 (-2.32%)
NVDA   383.03 (-4.51%)
NIO   7.31 (-1.35%)
BABA   78.36 (-0.39%)
AMD   118.86 (-5.12%)
T   15.80 (+1.02%)
F   12.03 (-4.45%)
MU   68.44 (-4.53%)
CGC   0.80 (-5.39%)
GE   100.36 (-1.99%)
DIS   87.42 (-0.46%)
AMC   4.41 (-4.75%)
PFE   37.59 (+1.57%)
PYPL   61.35 (-1.13%)
NFLX   391.19 (-0.46%)
S&P 500   4,172.98 (-0.77%)
DOW   32,815.86 (-0.69%)
QQQ   346.91 (-0.88%)
AAPL   178.67 (+0.77%)
MSFT   328.38 (-0.85%)
META   261.56 (-0.37%)
GOOGL   122.88 (-0.64%)
AMZN   119.25 (-1.98%)
TSLA   196.50 (-2.32%)
NVDA   383.03 (-4.51%)
NIO   7.31 (-1.35%)
BABA   78.36 (-0.39%)
AMD   118.86 (-5.12%)
T   15.80 (+1.02%)
F   12.03 (-4.45%)
MU   68.44 (-4.53%)
CGC   0.80 (-5.39%)
GE   100.36 (-1.99%)
DIS   87.42 (-0.46%)
AMC   4.41 (-4.75%)
PFE   37.59 (+1.57%)
PYPL   61.35 (-1.13%)
NFLX   391.19 (-0.46%)
NASDAQ:LPCN

Lipocine (LPCN) Stock Forecast, Price & News

$4.70
+0.04 (+0.86%)
(As of 12:17 PM ET)
Compare
Today's Range
$4.51
$4.77
50-Day Range
$3.53
$5.63
52-Week Range
$3.30
$16.15
Volume
5,981 shs
Average Volume
19,749 shs
Market Capitalization
$24.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$68.00

Lipocine MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
1,346.8% Upside
$68.00 Price Target
Short Interest
Healthy
1.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Lipocine in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$109,646 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.42) to ($1.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

856th out of 1,006 stocks

Pharmaceutical Preparations Industry

429th out of 492 stocks


LPCN stock logo

About Lipocine (NASDAQ:LPCN) Stock

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Stock News Headlines

Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Soaring EV Industry Keeps Investor Focus on Lithium
The need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.
Recap: Lipocine Q1 Earnings
Lipocine: Q1 Earnings Snapshot
Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)
Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com
LPCN: 2022 Operational & Financial Update
Lipocine to Present at Biotech Showcase
See More Headlines
Receive LPCN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter.

LPCN Company Calendar

Last Earnings
3/10/2023
Today
5/31/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPCN
Employees
13
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$68.00
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$68.00
Forecasted Upside/Downside
+1,346.8%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-10,760,000.00
Pretax Margin
-2,007.21%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$6.14 per share

Miscellaneous

Free Float
4,933,000
Market Cap
$24.44 million
Optionable
Optionable
Beta
0.93

Social Links


Key Executives

  • Mahesh V. PatelMahesh V. Patel
    President, Chief Executive Officer & Director
  • George G Nomikos
    Chief Medical Officer
  • Anthony DelConte
    Chief Medical Director
  • Nachiappan Chidambaram
    Vice President-Product Development
  • Krista Fogarty
    Chief Accounting Officer













LPCN Stock - Frequently Asked Questions

What is Lipocine's stock price forecast for 2023?

0 Wall Street analysts have issued 1-year price objectives for Lipocine's shares. Their LPCN share price forecasts range from $68.00 to $68.00. On average, they expect the company's share price to reach $68.00 in the next twelve months. This suggests a possible upside of 1,346.8% from the stock's current price.
View analysts price targets for LPCN
or view top-rated stocks among Wall Street analysts.

How have LPCN shares performed in 2023?

Lipocine's stock was trading at $6.7626 on January 1st, 2023. Since then, LPCN stock has decreased by 30.5% and is now trading at $4.70.
View the best growth stocks for 2023 here
.

Are investors shorting Lipocine?

Lipocine saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 80,100 shares, an increase of 32.0% from the April 30th total of 60,700 shares. Based on an average daily volume of 26,100 shares, the short-interest ratio is presently 3.1 days. Currently, 1.6% of the shares of the stock are short sold.
View Lipocine's Short Interest
.

When is Lipocine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our LPCN earnings forecast
.

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) released its quarterly earnings data on Friday, March, 10th. The specialty pharmaceutical company reported ($0.51) EPS for the quarter.

When did Lipocine's stock split?

Lipocine's stock reverse split before market open on Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

What other stocks do shareholders of Lipocine own?
What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Who are Lipocine's major shareholders?

Lipocine's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.66%), Wealth Effects LLC (0.85%), Two Sigma Investments LP (4.88%), Price T Rowe Associates Inc. MD (3.36%), Two Sigma Advisers LP (2.54%) and Group One Trading L.P. (0.00%). Insiders that own company stock include John W Higuchi, Krista Fogarty, Mahesh V Patel, Morgan R Brown, Richard Dana Ono and Spyros Papapetropoulos.
View institutional ownership trends
.

How do I buy shares of Lipocine?

Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $4.70.

How much money does Lipocine make?

Lipocine (NASDAQ:LPCN) has a market capitalization of $24.44 million and generates $500,000.00 in revenue each year. The specialty pharmaceutical company earns $-10,760,000.00 in net income (profit) each year or ($2.3809) on an earnings per share basis.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The official website for the company is www.lipocine.com. The specialty pharmaceutical company can be reached via phone at (801) 994-7383, via email at john.woolford@westwicke.co, or via fax at 801-994-7388.

This page (NASDAQ:LPCN) was last updated on 5/31/2023 by MarketBeat.com Staff

My Account -